Better data needed from pregnancy registries

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 85, Issue 2, 2009, Pages 109-111

  Briggs, Gerald G ^a   Polifka, Janine ^b   Balken, Elizabeth ^c   Berard, Anick ^c   Braddock, Stephen ^c   Chambers, Christina ^c   Einarson, Adrienne ^c   Gaffaney, Cecilia Lyons ^c   Quinn, Dee ^c   Koren, Gideon ^c   Jones, Kenneth ^c   Lamm, Steve ^c   Miller, Richard ^c   Riordan, Sara ^c   Robinson, Luther ^c   Soldin, Offie ^c   Wisner, Katherine ^c   Wolfe, Lori ^c  

^a MILLER CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Exposure dose; Exposure timing; Pregnancy registries

Indexed keywords

AMFEBUTAMONE; BOVINE SERUM ALBUMIN; LAMOTRIGINE; MONTELUKAST; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN;

ADVERSE OUTCOME; AREA UNDER THE CURVE; BIRTH DEFECT; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; CONSENSUS; DEVELOPMENTAL DISORDER; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; EMBRYOTOXICITY; ENVIRONMENTAL EXPOSURE; FATALITY; FETOTOXICITY; GESTATIONAL AGE; GROWTH DISORDER; HEALTH CARE ORGANIZATION; HUMAN; MENSTRUAL CYCLE; NONHUMAN; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; SHORT SURVEY; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; CONGENITAL ABNORMALITIES; CONSENSUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; PHARMACEUTICAL PREPARATIONS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; RISK FACTORS; TIME FACTORS;

EID: 62949200322     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20551     Document Type: Short Survey

References (7)

1. Halls SB. 2008. Body surface area calculator for medication doses. Available at: http://www.halls.md/body-surface-area/bsa.htm. Accessed August 20, 2008.
2. Jones KL. 2006. Morphogenesis and dysmorphogenesis. In: Jones KL. Smith's recognizable patterns of human malformations. 6th ed. Philadelphia: W.B. Saunders. p. 794.
3. Manning FA. 2004. General principles and applications of ultrasonography. In: Creasy RK, Resnik R, Iams JD, editors. Maternal-fetal medicine. 5th ed. Philadelphia: Saunders. p. 321.
4. Rodier PM. 2005. Is the fetus susceptible to adverse effects of a chemical or physical agent after the first trimester? Teratology primer. The Teratology Society. p. 9.
5. Schardein JL. 2000a. Principles of teratogenesis applicable to drug and chemical exposure. In: Chemically induced birth defects. 3rd ed. New York: Marcel Dekker. p. 6.
6. Schardein JL. 2000b. Principles of teratogenesis applicable to drug and chemical exposure. In: Chemically induced birth defects. 3rd ed. New York: Marcel Dekker. p. 9.
7. U.S. Environmental Protection Agency. 1991. Guidelines for developmental toxicity risk assessment. U.S. Environmental Protection Agency. Risk Assessment Forum, Washington, DC, EPA/600/FR-91/001. Available at: http://cfpub.epa.gov/ ncea/cfm/recordisplay.cfm?deid=23162. Accessed August 18, 2008.